For our June 10, 2017 meeting Dr. Jack Watkins from Bristol-Myers Squibb will be speaking on immunotherapy and its use in the treatment of multiple myeloma. As you may know, immunotherapy is treatment that helps your immune system fight your cancer. (American Cancer Society's definition of immunotherapy) It is a fast-moving area of research, especially for the treatment of multiple myeloma. In 2015 the first two immunotherapy agents - Darzalex™ (daratumumab, Genmab/Janssen) and Empliciti™ (elotuzumab, Bristol-Myers Squibb/AbbVie) - were approved by the FDA for use in treating relapsed /refractory patients. More immunotherapy agents are in the pipeline.